Evidence map›Paper›PMID 38003471›Full record

ArticleInternational journal of molecular sciences2023

IK Channel-Independent Effects of Clotrimazole and Senicapoc on Cancer Cells Viability and Migration.

Paolo Zuccolini, Raffaella Barbieri, Francesca Sbrana, Cristiana Picco, Paola Gavazzo, Michael Pusch

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Emerging Therapeutic Options in Pancreatic Cancer Management.International journal of molecular sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Paolo ZuccoliniBiophysics Institute, National Research Council, 16149 Genova, Italy.
Raffaella BarbieriBiophysics Institute, National Research Council, 16149 Genova, Italy.
Francesca SbranaBiophysics Institute, National Research Council, 16149 Genova, Italy.
Cristiana PiccoBiophysics Institute, National Research Council, 16149 Genova, Italy.ORCID 0000-0002-6512-1802
Paola GavazzoBiophysics Institute, National Research Council, 16149 Genova, Italy.ORCID 0000-0002-2016-4702
Michael PuschBiophysics Institute, National Research Council, 16149 Genova, Italy.ORCID 0000-0002-8644-8847

Funding

Fondazione Cariplo GJC22008Italian Association for Cancer Research IG 21558MUR Italy PRIN 20174TB8KWTelethon Foundation GMR22T102
6 · The paper itself

Abstract

Many studies highlighted the importance of the IK channel for the proliferation and the migration of different types of cancer cells, showing how IK blockers could slow down cancer growth. Based on these data, we wanted to characterize the effects of IK blockers on melanoma metastatic cells and to understand if such effects were exclusively IK-dependent. For this purpose, we employed two different blockers, namely clotrimazole and senicapoc, and two cell lines: metastatic melanoma WM266-4 and pancreatic cancer Panc-1, which is reported to have little or no IK expression. Clotrimazole and senicapoc induced a decrease in viability and the migration of both WM266-4 and Panc-1 cells irrespective of IK expression levels. Patch-clamp experiments on WM266-4 cells revealed Ca

Indexed as

ClotrimazoleMelanomaAcetamidesHumansPotassium Channel BlockersTriphenylmethyl CompoundsAcetamidesClotrimazolePotassium Channel BlockerssenicapocTriphenylmethyl CompoundsblockerscancerclotrimazoleIKKCa3.1KCNN4melanomapancreatic duct adenocarcinoma (PDAC)senicapoc

Identifiers

PMID38003471
PMCPMC10671816

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.